**OriGene Technologies, Inc.**
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

# Product datasheet for TG320517

## RSK1 p90 (RPS6KA1) Human shRNA Plasmid Kit (Locus ID 6195)

### Product data:

| | |
|---|---|
| **Product Type:** | shRNA Plasmids |
| **Product Name:** | RSK1 p90 (RPS6KA1) Human shRNA Plasmid Kit (Locus ID 6195) |
| **Locus ID:** | 6195 |
| **Synonyms:** | HU-1; MAPKAPK1; MAPKAPK1A; p90Rsk; RSK; RSK1 |
| **Vector:** | pGFP-V-RS (TR30007) |
| **E. coli Selection:** | Kanamycin |
| **Mammalian Cell Selection:** | Puromycin |
| **Format:** | Retroviral plasmids |
| **Components:** | RPS6KA1 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 6195). 5µg purified plasmid DNA per construct<br>29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free. |
| **RefSeq:** | NM_001006665, NM_002953, NM_001330441, NM_002953.1, NM_002953.2, NM_002953.3, BC014966, BC014966.1, BC039069, BM836865 |
| **UniProt ID:** | Q15418 |
| **Summary:** | This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 nonidentical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008] |
| **shRNA Design:** | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |

View online »

**Performance Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).